Real-world first-line afatinib for advanced
Afatinib
epidermal growth factor receptor (EGFR)
first-line
non-small cell lung cancer (NSCLC)
real-world
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
30 Nov 2023
30 Nov 2023
Historique:
received:
12
06
2023
accepted:
17
11
2023
medline:
13
12
2023
pubmed:
13
12
2023
entrez:
13
12
2023
Statut:
ppublish
Résumé
Data from clinical trials and real-world studies show that afatinib is effective in treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor ( The study was a retrospective, multicenter (15 sites) review of electronic records of Korean adult patients (aged >20 years) with advanced Overall, median PFS was 20.2 months and median OS was 48.6 months. OS rates at 36 and 60 months were 60.1% and 42.3%, respectively. Presence Afatinib was effective in Korean patients with
Sections du résumé
Background
UNASSIGNED
Data from clinical trials and real-world studies show that afatinib is effective in treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (
Methods
UNASSIGNED
The study was a retrospective, multicenter (15 sites) review of electronic records of Korean adult patients (aged >20 years) with advanced
Results
UNASSIGNED
Overall, median PFS was 20.2 months and median OS was 48.6 months. OS rates at 36 and 60 months were 60.1% and 42.3%, respectively. Presence
Conclusions
UNASSIGNED
Afatinib was effective in Korean patients with
Identifiants
pubmed: 38090523
doi: 10.21037/tlcr-23-383
pii: tlcr-12-11-2275
pmc: PMC10713275
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2275-2282Informations de copyright
2023 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-383/coif). Y.S.C. declares being a stockholder in BicBio; Y.C.K. has received grants from AstraZeneca and honoraria from AstraZeneca, Merck Sharp & Dohme, Roche, Novartis, Janssen, Amgen, Ono Pharma, Bristol Myers Squibb, and Takeda; I.J.O. has received grants from AstraZeneca and Roche, personal fees from Gencurix, Janssen, Merck Sharp & Dohme, Ono Pharma, Panagene, Pfizer, Roche, and Yuhan, and honoraria from Amgen, AstraZeneca, Eli Lilly, Janssen, Menarini, Merck Sharp & Dohme, Novartis, Pfizer, and Yuhan; S.Y.L. has received honoraria from Boehringer Ingelheim; T.W.J. has received honoraria from Boehringer Ingelheim. The other authors have no conflicts of interest to disclose.